^
Association details:
| Biomarker: | GOPC-ROS1 fusion |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report
Published date:
07/11/2020
Excerpt:
A patient with high-grade serous ovarian carcinoma...NGS revealed the patient harboring a GOPC-ROS1 fusion...Therefore, the patient received crizotinib treatment. A rapid, favorable clinical response (partial response at 1 month) was observed, with further pathological response monitored and evaluated in follow-up interrogation.
DOI:
10.1634/theoncologist.2019-0609
